CD8A and neoplasm: Analysis of IFN-γ expression by tumor-infiltrating CD3+, CD4+, and CD8+ central and effector memory T cells revealed a significantly higher level in the triple combination (CD3+/CD4+ CM, **P < 0.005 vs carboplatin + pembrolizumab; CD8+ CM, *P < 0.05 vs carboplatin + pembrolizumab), (CD3+ EM,*P < 0.05, CD4+ EM, **P < 0.005, CD8+ EM,*P < 0.05) (Fig. 6i–k).